文献速递鼻科

度普利尤单抗减轻CRSwNP患者全鼻窦浑浊及相关症状

Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
PubMed 文献 · Rhinology · 2020-01-01

一项16周随机双盲安慰剂对照2a期研究纳入60例CRSwNP成人,评估度普利尤单抗300mg每周皮下注射对鼻窦浑浊的影响。结果显示度普利尤单抗显著改善所有单个鼻窦的LMK浑浊评分,且与嗅觉/味觉症状相关。

要点

  • 度普利尤单抗显著改善CRSwNP患者所有鼻窦的LMK浑浊评分
  • 基线LMK评分与鼻息肉严重度及嗅觉丧失相关
  • 最常见不良事件为鼻咽炎、注射部位反应和头痛

核心结论

  • 在CRSwNP患者中,度普利尤单抗治疗减少所有鼻窦的浑浊及相关症状。

研究设计与样本

  • 16周随机、双盲、安慰剂对照、平行组研究,纳入60例成人CRSwNP患者。
  • 患者每周皮下注射度普利尤单抗300mg或安慰剂,并每日使用糠酸莫米松鼻喷雾剂。

主要发现

  • 基线LMK评分均值±SD为18.7±5.5(安慰剂)和18.6±5.0(度普利尤单抗),提示严重疾病伴所有鼻窦广泛浑浊。
  • 基线LMK和zLMK评分与NPS严重度及嗅觉丧失相关(每日症状、SNOT-22嗅觉/味觉、UPSIT嗅觉丧失)。
  • 第16周时,度普利尤单抗组所有单个鼻窦的LMK浑浊评分较安慰剂显著改善。
  • 度普利尤单抗在zLMK评分上显示相似疗效,与LMK仅小差异,并与SNOT-22嗅觉/味觉相关。
  • 最常见不良事件为鼻咽炎、注射部位反应和头痛。

关键数值与推荐

  • 度普利尤单抗300mg每周皮下注射,联合每日糠酸莫米松鼻喷雾剂。
  • 鼻窦浑浊采用标准LMK和Zinreich改良LMK(zLMK)评分评估。

临床怎么用

  • 度普利尤单抗可用于CRSwNP患者减轻全鼻窦浑浊及相关症状。
  • 鼻窦浑浊评分与鼻息肉负担和嗅觉症状相关,可作为评估指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with substantial sinus opacification. In a phase 2a study (NCT01920893), dupilumab, a fully human anti-IL-4Rα monoclonal antibody, improved outcomes in CRSwNP refractory to intranasal corticosteroids. We evaluated dupilumab’s effect on sinus opacification in relation to effects on nasal polyp burden, symptoms, and health-related quality of life (HRQoL) in patients with CRSwNP. METHODOLOGY: 16-week randomized, double-blind, placebo-controlled, parallel-group study in 60 adults with CRSwNP. Patients received weekly subcutaneous dupilumab 300-mg or placebo and daily mometasone furoate nasal spray. Sinus opacification was assessed using standard and Zinreich-modified Lundâ€"Mackay (zLMK) scoring. Correlation was assessed between zLMK score and CRSwNP endpoints, including nasal polyp score (NPS), SNOT-22, daily symptom scores, and UPSIT smell-test score. RESULTS: Baseline characteristics were similar across treatment groups. Mean plus/minus SD baseline LMK scores of 18.7 plus/minus 5.5 (placebo) and 18.6 plus/minus 5.0 (dupilumab) indicated severe disease with extensive opacification involving all sinuses. Baseline LMK and LMK scores correlated with NPS severity and loss of sense of smell (daily symptoms; SNOT-22 smell/taste; loss of sense of smell [UPSIT]). At Week 16, dupilumab-treated patients had significantly improved sinus opacification measured by LMK in all individual sinuses vs placebo. Dupilumab also showed similar efficacy with zLMK, with only small differences from LMK, and correlated with SNOT22 smell/taste. The most common adverse events were nasopharyngitis, injection-site reactions, and headache. CONCLUSIONS: In patients with CRSwNP, baseline LMK showed extensive sinus opacification and correlated with symptoms, HRQoL, and hyposmia. Dupilumab treatment reduces opacification across all sinuses and related symptoms in patients with CRSwNP.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Bachert C, Zinreich SJ, Hellings PW, et al. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology. 2020. PMID: 31671432. doi:10.4193/Rhin18.282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。